Why the study?
Does type 2 diabetes mellitus affect the thrombolytic efficacy of streptokinase (measured by ST-segment resolution) in patients with acute STEMI?
Does type 2 diabetes mellitus affect the thrombolytic efficacy of streptokinase (measured by ST-segment resolution) in patients with acute STEMI?
Type 2 diabetes mellitus is associated with significantly poorer ST-segment resolution following streptokinase thrombolysis in acute STEMI patients compared to non-diabetics.
Diabetes associated with poorer ST-resolution after streptokinase; leaves open impact on outcomes and need for alternative reperfusion strategies.
A prospective interventional study was carried out to compare the thrombolytic effect of streptokinase between diabetic and non-diabetic myocardial infarction patients. Out of 187 study subjects with acute ST segment elevation myocardial infarction (STEMI), admitted at coronary care unit, 126 patients were non-diabetic and 61 patients were diabetic. Streptokinase was administered to all patients. Resolution (reduction) of elevated ST segment was evaluated after 90 minutes of streptokinase administration. Successful reperfusion (?70% ST-resolution) was significantly higher in non-diabetic than diabetic (p<0.001), while failed reperfusion (<30% ST resolution) was significantly higher in diabetic patients (p<0.001). It may be concluded that diabetes mellitus might affect the thrombolytic outcome of acute myocardial infarction patients with diabetes mellitus.
No takes yet. Share an insight, caveat, or question.
Hossain et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: